Breast Cancer

An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?

Dr. Sparano discusses the implications of TAILORx, the first trial to use Oncotype DX in clinical decision making.

In a first-of-its-kind study, researchers analyzed how Twitter users talk about breast cancer on the social media platform.

We take a look at how a healthy diet can improve quality of life in breast cancer survivors.

A novel cancer vaccine targeting HER2-positive malignancies has progressed quickly from mouse trials into early-phase human trials, with promising results.

Different cytotoxic chemotherapy regimens are associated with varying rates of hospitalization following their use in older women with stage IV breast cancer.

The Short-HER study was unable to show noninferiority of 9 weeks of trastuzumab compared with the standard 1 year in women with HER2-positive breast cancer.

Nearly 10 years of follow-up from a large clinical trial have confirmed that axillary dissection is not necessary in patients with early breast cancer.

Survival has increased substantially for young women with breast cancer since 1975, though it has largely reached a plateau since around 2005.

Breast and gynecologic cancer patients undergoing chemotherapy may experience improvement in cancer-related fatigue with integrative medicine approaches.

A new laboratory study has shed some light on how mitochondrial metabolism is altered in breast cancer.

Outcomes for patients with HER2-positive breast cancer did not differ when treated with sequential chemotherapy plus trastuzumab compared with a concurrent approach.

A 17-gene signature derived from circulating tumor cells was found to correlate with response to therapy in patients with breast cancer.

Treatment with talazoparib improved quality of life vs physician’s choice of chemotherapy in patients with HER2-negative advanced breast cancer.

A study using multigene panel testing identified several pathogenic variants associated with an increased risk of triple-negative breast cancer.

This article will present feasible weight loss interventions, and will discuss practical implications of ongoing chemotherapy and endocrine therapy with regard to weight gain, and the impact of obesity on therapy-related conditions during breast cancer survivorship.

A chest wall recurrence of breast cancer following mastectomy is a complex clinical problem that can push centers to the limits of their resources.

The presence of HER3 expression and a high HER2/CEP17 ratio distinguish a group of invasive HER2-positive ductal breast cancer patients who have a worse prognosis.

Patients treated with anti–PD-1 or anti–PD-L1 inhibitors in clinical trials were successfully retreated with the inhibitors after discontinuing the treatment.

A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines.

Internal mammary chain radiation therapy for breast cancer is associated with increased cardiac toxicity, in particular when paired with anthracyclines.

Many breast cancer patients report that clinicians do not engage adequately regarding management of financial toxicity associated with their diagnosis, according to a new survey.

The addition of bevacizumab to adjuvant chemotherapy regimens does not improve survival in women with high-risk breast cancer.

Germline BRCA mutations and other HR genes may offer biomarkers for response to this treatment.

The gardening intervention led to improvements in physical activity measures and other health outcomes in breast cancer survivors.

An update to guidelines from ASCO on the optimal management of patients with HER2+ breast cancer offers recommendations on timing and sequence of therapies.

Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer.

The inverse association with premenopausal breast cancer was seen across the entire distribution of BMI, and at a higher magnitude than previously reported.

The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.

This article discusses the ways in which pathologic regional nodal status affects clinical decisions about locoregional and systemic treatment, reviews published literature and guidelines, and aims to provide a practical perspective on treatment approach in the face of a broad range of data and recommendations.